{"id":"NCT04250337","sponsor":"Eli Lilly and Company","briefTitle":"Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-02-03","primaryCompletion":"2021-08-11","completion":"2021-09-16","firstPosted":"2020-01-31","resultsPosted":"2022-05-02","lastUpdate":"2022-05-09"},"enrollment":228,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"BIOLOGICAL","name":"Lebrikizumab","otherNames":["LY3650150","DRM06"]},{"type":"OTHER","name":"Placebo","otherNames":[]},{"type":"OTHER","name":"Topical Corticosteroid","otherNames":[]}],"arms":[{"label":"Lebrikizumab + Topical Corticosteroid","type":"EXPERIMENTAL"},{"label":"Placebo + Topical Corticosteroid","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, double-blind, placebo-controlled, parallel-group study which is 16 weeks in duration. The study is designed to evaluate the safety and efficacy of lebrikizumab when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination with TCS treatment for moderate-to-severe atopic dermatitis.","primaryOutcome":{"measure":"Percentage of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Reduction â‰¥2-points From Baseline to Week 16.","timeFrame":"Baseline to Week 16","effectByArm":[{"arm":"Placebo +Topical Corticosteroid","deltaMin":22.1,"sd":null},{"arm":"Lebrikizumab + Topical Corticosteroid","deltaMin":41.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.011"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":63,"countries":["United States","Canada","Germany","Poland"]},"refs":{"pmids":["36630140"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/4gJ6pg3ypXbcm8LEXb9M3b"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":75},"commonTop":["Nasopharyngitis","Headache","Conjunctivitis","Dermatitis atopic","Hypertension"]}}